Document is current
Any future updates will be listed below
-
Authors
Jiang, Xiaoyi
Wang, Jian
Zheng, Xichen
Liu, Zhida
Zhang, Xinyu
Li, Yuwei
Wilhelm, Jonathan
Cao, Jun
Huang, Gang
Zhang, Jinlan
Sumer, Baran
Lea, Jayanthi
Lu, Zhigang
Gao, Jinming
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03323398 at ClinicalTrials.govnct03445533 at ClinicalTrials.govDocuments that mention this clinical trial
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
https://doi.org/10.1136/jitc-2021-003960
Documents that mention this clinical trial
Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).
https://doi.org/10.1200/jco.2024.42.17_suppl.lba9516
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
https://doi.org/10.1136/jitc-2021-003960
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
https://doi.org/10.1136/jitc-2021-002876
B cells imprint adoptively transferred CD8 <sup>+</sup> T cells with enhanced tumor immunity
https://doi.org/10.1136/jitc-2021-003078
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
https://doi.org/10.1200/jco.24.00727
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01 CA192221)
National Cancer Institute (U01 CA218422)
National Natural Science Foundation of China (81873438)
National Natural Science Foundation of China (81873922)
- License Information
